Pancreatic Dysfunction and Diabetes: Significance and Challenges of the New Pancreatic Disability System

The pancreatic disability registration system, introduced in Korea in 2026, represents an importantstep toward recognizing the burden of pancreatic dysfunction beyond glycemic control. Patients withtype 1 diabetes mellitus and those with insulin-requiring pancreatogenic diabetes face intensive selfmanagementdemands, while some patients with pancreatogenic diabetes also experience exocrinepancreatic insufficiency. Despite advances in diabetes technologies, such as continuous glucosemonitoring and automated insulin delivery systems, substantial treatment burden, psychosocial distress,and functional limitations remain. Disability assessment should therefore extend beyond biologicalmarkers such as C-peptide to include treatment intensity, functional impairment, and the burdenexperienced by patients. Successful implementation of the pancreatic disability system requires morethan registration alone; equitable access to diabetes technologies, structured education, multidisciplinarycare, and lifelong support are essential. This article discusses the clinical significance of the newlyintroduced pancreatic disability system and the challenges involved in developing patient-centereddisability assessment and support for individuals with pancreatic dysfunction.